Systematic review of pharmacological treatments in fragile X syndrome (Q24647106)

13 March 2019

22 April 2019

25 April 2019

17 September 2019

7 November 2019

15 August 2020

2 October 2023

on focus list of Wikimedia project

3 October 2023

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2377-9-53

0 references

cites work

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Advances in the treatment of fragile X syndrome

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Using percentile schedules to increase eye contact in children with Fragile X syndrome

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Measurement of problem behaviour during medication evaluations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

The fragile X continuum: new advances and perspectives

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

The fragile X prevalence paradox

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Characterization of potential outcome measures for future clinical trials in fragile X syndrome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Fragile X syndrome: assessment and treatment implications

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Brief review of current research in FXS: implications for treatment with psychotropic medication

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Therapeutic implications of the mGluR theory of fragile X mental retardation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Psychopharmacology in fragile X syndrome--present and future

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Screening for fragile X syndrome: a literature review and modelling study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

FMR1 and the fragile X syndrome: human genome epidemiology review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Folic acid blinded trial in identical twins with fragile X syndrome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Oral folic acid versus placebo in the treatment of males with the fragile X syndrome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

High dose folic acid treatment of fragile (X) males

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Autism profiles of males with fragile X syndrome

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX).

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Folic acid treatment in males and females with fragile-(X)-syndrome.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Folic acid treatment of fragile X males: a further study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: a double-blind, placebo-controlled study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Autism spectrum phenotype in males and females with fragile X full mutation and premutation.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Folic acid therapy in the fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

The acquisition of stimulus equivalence in individuals with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Special Topics in Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-53

Open-label memantine in fragile X syndrome.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

The fragile X syndrome. A study of 83 families.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770029

A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys

28 November 2018

1 reference

12 December 2020

A controlled study of folic acid treatment in three fragile X syndrome males

1 reference

12 December 2020

A controlled trial of stimulant medication in children with the fragile X syndrome

1 reference

12 December 2020

Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin for the treatment of fragile X syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-9-53

1 reference

Dimensions Publication ID

3584463

1046283177

0 references

3584463

1 reference

1 reference

1 reference